News
FDA Pre-NDA Meeting Outcomes : TLX591-CDx (illumet™)
MELBOURNE (Australia) and INDIANAPOLIS (USA) – 28 August 2019. Telix had a pre-NDA meeting with the United States Food and Drug Administration (FDA) on the 24th of July to discuss the Company’s plan
Melbourne (Australia) and Indianapolis (USA) – Aug. 28, 2019
Telix had a pre-NDA meeting with the United States Food and Drug Administration (FDA) on the 24th of July to discuss the Company’s plan for the submission of a New Drug Application (NDA) for TLX591-CDx, (kit for the preparation of 68Ga-PSMA, trademarked as illumet™ in the United States). The Company has now received the formal meeting minutes from the FDA and can reliably report on the outcomes.
To read the full media release click here.
More Articles
News
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...
News
Telix Pharmaceuticals Program Update Q3 2019
MELBOURNE (Australia) – Nov. 4, 2019 - Telix Pharmaceuticals Ltd Program Update Q3, 2019
News
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
Melbourne and Adelaide (Australia) – 30 October 2019. Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered...
News
Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, to speak at Jefferies 2019 London Healthcare Conference
LONDON (United Kingdom) – November 19, 2019 – Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, to speak at Jefferies...